2006 - Member of the National Academy of Medicine (NAM)
2000 - Fellow of the American Association for the Advancement of Science (AAAS)
Kathleen M. Giacomini mostly deals with Pharmacology, Transporter, Biochemistry, Organic cation transport proteins and Genetics. The study incorporates disciplines such as Pharmacogenetics and Kidney in addition to Pharmacology. Her work deals with themes such as Xenobiotic, Drug development, Efflux and Toxicity, which intersect with Transporter.
She interconnects Metformin, Internal medicine, Membrane potential and Endocrinology in the investigation of issues within Organic cation transport proteins. Kathleen M. Giacomini usually deals with Pharmacokinetics and limits it to topics linked to Kidney metabolism and Renal Elimination and SLC47A2. Her Drug research includes elements of Quantitative structure–activity relationship, Bioinformatics, Chemical space and In silico.
Kathleen M. Giacomini focuses on Biochemistry, Pharmacology, Transporter, Internal medicine and Genetics. Biochemistry and Choroid plexus are frequently intertwined in her study. Her Pharmacology study incorporates themes from Metformin, Kidney and Organic cation transport proteins.
The Metformin study combines topics in areas such as Pharmacogenetics and Type 2 diabetes. Her Transporter study frequently intersects with other fields, such as Drug development. Her Internal medicine research is multidisciplinary, relying on both Endocrinology and Oncology.
Kathleen M. Giacomini spends much of her time researching Pharmacology, Transporter, Drug, Drug development and Biochemistry. Her research in Pharmacology intersects with topics in Metformin, Uric acid, Thiamine transporter, Organic cation transport proteins and Organic anion transporter 1. Her study in Organic cation transport proteins focuses on SLC47A1 in particular.
Her Transporter research includes themes of Protein structure, Carnitine and Function. Her Drug study combines topics from a wide range of disciplines, such as Renal drug, Pharmacokinetics and Excipient. Her studies in Drug development integrate themes in fields like Clinical trial, IC50, Safety monitoring, Membrane Transport Modulators and Computational biology.
Her primary areas of investigation include Transporter, Pharmacology, Drug development, Organic cation transport proteins and Organic anion transporter 1. In her work, Type 2 diabetes and Pharmacogenetics is strongly intertwined with Metformin, which is a subfield of Pharmacology. Her Drug development research is multidisciplinary, incorporating elements of Abcg2, Pharmacogenomic Variants, Organic anion-transporting polypeptide, Membrane Transport Modulators and Computational biology.
Her studies deal with areas such as Docking, Molecular Docking Simulation, HEK 293 cells, In silico and Drug discovery as well as Organic cation transport proteins. Her Organic anion transporter 1 research is within the category of Biochemistry. Her Renal physiology study in the realm of Biochemistry interacts with subjects such as Glutathione disulfide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Membrane transporters in drug development.
Kathleen M. Giacomini;Shiew Mei Huang;Donald J. Tweedie;Leslie Z. Benet.
Nature Reviews Drug Discovery (2010)
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
Yan Shu;Steven A. Sheardown;Chaline Brown;Ryan P. Owen.
Journal of Clinical Investigation (2007)
SLC transporters as therapeutic targets: emerging opportunities
Lawrence Lin;Sook Wah Yee;Richard B. Kim;Kathleen M. Giacomini.
Nature Reviews Drug Discovery (2015)
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Y Shu;Y Shu;C Brown;RA Castro;RJ Shi.
Clinical Pharmacology & Therapeutics (2008)
Cloning and Functional Expression of a Human Liver Organic Cation Transporter
Lei Zhang;Mark J. Dresser;Andrew T. Gray;Spencer C. Yost.
Molecular Pharmacology (1997)
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.
Deanna L. Kroetz;Christiane Pauli-Magnus;Laura M. Hodges;Conrad C. Huang.
The concentrative nucleoside transporter family, SLC28.
Jennifer H. Gray;Ryan P. Owen;Kathleen M. Giacomini.
Pflügers Archiv: European Journal of Physiology (2004)
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Shuzhong Zhang;Katherine S. Lovejoy;James E. Shima;Leah L. Lagpacan.
Cancer Research (2006)
Metformin pathways: pharmacokinetics and pharmacodynamics
Li Gong;Srijib Goswami;Kathleen M. Giacomini;Russ B. Altman.
Pharmacogenetics and Genomics (2012)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Russell A. Wilke;Debbie W. Lin;Dan M. Roden;Paul B. Watkins.
Nature Reviews Drug Discovery (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: